Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing all-case surveillance of Raiatt MIBG-I 131 Injection
jRCT2031220066Active, not recruiting
- Sponsor
- PDRadiopharma Inc.
- Start
- Apr 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label, single-arm trial of Iobenguane I-131 in pheochromocytoma and Paraganglioma (PGL), sponsored by PDRadiopharma Inc. Primary endpoints: Case composition metrics, Safety – adverse drug reactions and 5 more. Started Apr 2022; status: active, not recruiting.
02
Drugs
Iobenguane I-131
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on jRCT2031220066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220066.